Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2+ Metastatic Breast Cancer (MBC) Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

NCT00928330
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

NCT03901339
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jun 11, 2026, 5:26 AM EDT
Active, not recruiting No phase listed Observational

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

NCT06495164
View directory record Official record
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed No phase listed Observational

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

NCT06961331
View directory record Official record
Conditions
Metastatic HER2+ Advanced Breast Cancer
Interventions
Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

NCT02229149
View directory record Official record
Conditions
Breast Neoplasms, Malignant Tumor of the Breast
Interventions
Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Multiple Locations, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

NCT02659514
View directory record Official record
Conditions
Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

NCT04740918
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab Emtansine, Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Letrozole, Fulvestrant
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

NCT00567190
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pertuzumab, Placebo, Trastuzumab, Docetaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
159
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jun 11, 2026, 5:26 AM EDT
Withdrawn Phase 1 Interventional

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

NCT04872608
View directory record Official record
Conditions
Metastatic Breast Cancer, Unresectable Breast Cancer
Interventions
Letrozole, Palbociclib, Onapristone ER
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

NCT00915603
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Everolimus, Bevacizumab, Paclitaxel, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
LaVerne, California • Norwich, Connecticut • Aventura, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2014 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

NCT03321981
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Zenocutuzumab, Trastuzumab, Vinorelbine, Endocrine therapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 3 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

NCT03326674
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel and Capecitabine, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
90
States / cities
Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jun 11, 2026, 5:26 AM EDT
Completed No phase listed Observational Results available

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

NCT05141708
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Neoplasms
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Copanlisib, Pertuzumab, Trastuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Interventions
RYZ101
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

NCT05501769
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471 in combination with Everolimus
Drug
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Letrozole, Trastuzumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jun 11, 2026, 5:26 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193
View directory record Official record
Conditions
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions
OP-3136, Fulvestrant, Palazestrant
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Sarasota, Florida • New Orleans, Louisiana • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 11, 2026, 5:26 AM EDT